Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yuriy Zgherea

Allergy & Immunology Wyoming, MN Medical Doctor

NPI 1891941373 CMS profile 815710

5200 Fairview Blvd, Wyoming, MN 55092

Open in the dashboard

General payments

$1,676

6 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yuriy Zgherea of Wyoming, MN is reported in the CMS Open Payments database as having received $1,676 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78 2
2022 General $94 1
2019 General $1,504 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yuriy Zgherea
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Yuriy Zgherea were reported at $78. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Yuriy Zgherea Allergy & Immunology median Middle half National median
2019 $1,504 $594 $163–$1,512 $163
2020 $0 $426 $106–$1,233 $114
2021 $0 $638 $157–$1,708 $132
2022 $94 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $78 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ALK-Abello, Inc $1,504 3 payments
  2. AstraZeneca Pharmaceuticals LP $94 1 payment
  3. Novartis Pharmaceuticals Corporation $53 1 payment
  4. Ionis Pharmaceuticals, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,400 1 payment
  2. Food and Beverage $251 4 payments
  3. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. Odactra $1,504 3 payments
  2. Grastek $1,456 2 payments
  3. Ragwitek $1,456 2 payments
  4. TEZSPIRE $94 1 payment
  5. Rhapsido $53 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,637

Median for Allergy/ Immunology: 449

Drug cost

$525,698

Median for Allergy/ Immunology: $169,700

Branded share of claims

44.4%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 188 $141,112
Dupixent Pen Dupilumab Brand 36 $139,280
Breo Ellipta Fluticasone/Vilanterol Brand 81 $42,478
Dupixent Syringe Dupilumab Brand 11 $40,885
Xolair Omalizumab Brand 13 $35,188
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 118 $33,759
Dulera Mometasone/Formoterol Brand 44 $20,364
Advair Hfa Fluticasone Propion/Salmeterol Brand 27 $13,515
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 62 $12,843
Incruse Ellipta Umeclidinium Bromide Brand 20 $9,950

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$88,166

Medicare's payments for the services billed

Medicare patients

79

Average age 63

Services billed

2,833

56 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 49%
Depression 30%
Diabetes 23%
Chronic kidney disease 19%
COPD 15%
Ischemic heart disease 14%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record